Recurrent Pericarditis Market Report 2026

The recurrent pericarditis market size has grown rapidly in recent years. It will grow from $0.79 billion in 2025 to $0.88 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to historical reliance on NSAIDs and colchicine, rising diagnosis of inflammatory heart conditions, established cardiology care pathways, increased availability of echocardiography, guideline driven anti inflammatory therapy use.

The recurrent pericarditis market size is expected to see rapid growth in the next few years. It will grow to $1.32 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to growing adoption of biologic drugs, improved recurrence risk stratification, expansion of specialty cardiology clinics, higher awareness of immune mediated pericarditis, increasing use of targeted cytokine inhibitors. Major trends in the forecast period include higher use of targeted biologic therapies, expansion of long term disease monitoring, growth in anti inflammatory combination therapy, increased adoption of IL-1 inhibitors, structured recurrence prevention protocols.

The growing emphasis on precision medicine approaches is expected to drive the growth of the recurrent pericarditis market going forward. Precision medicine is a healthcare strategy that customizes prevention and treatment plans for individual patients based on their genetic makeup, environment, and lifestyle. The rising focus on precision medicine is fueled by improved treatment outcomes, as therapies tailored to an individual’s genetic and biological profile enhance efficacy and reduce the risk of adverse effects. Recurrent pericarditis supports precision medicine by enabling targeted therapeutic approaches that focus on patient-specific inflammatory pathways, such as interleukin-1-mediated mechanisms, allowing for more personalized and effective disease management. For instance, in February 2025, according to NHS England, a UK-based public healthcare organization, in 2024 the NHS Genomic Medicine Service conducted over 810,000 genomic tests for patients across the life course in England, reflecting an 8% increase compared with 2023 and continuing year-on-year growth since the service was established. Therefore, the growing emphasis on precision medicine approaches is driving the growth of the recurrent pericarditis market.

Companies operating in the recurrent pericarditis market are focusing on developing anti-inflammatory and anti-fibrotic therapies to reduce pericardial inflammation, prevent long-term cardiac damage, improve patient quality of life, and minimize recurrence rates. Anti-inflammatory effects reduce inflammation in tissues, while anti-fibrotic effects prevent or reverse the formation of scar tissue, together helping to protect organs from damage and maintain normal function. For example, in October 2024, Cardiol Therapeutics Inc., a Canada-based clinical-stage life sciences company, advanced CardiolRx, a novel oral, non-immunosuppressive therapeutic for recurrent pericarditis that targets the NLRP3 inflammasome, a key upstream driver of IL-1-mediated inflammation. CardiolRx is being developed to prevent disease recurrence, particularly in patients who relapse after discontinuation of IL-1 blocker therapies such as rilonacept or anakinra. Through late-stage clinical programs, it aims to reduce pericarditis flares, alleviate chest pain, and normalize inflammatory markers (CRP).

In April 2024, Sanofi S.A., a France-based healthcare technology company, acquired Kiniksa Pharmaceuticals Limited for $2.5 billion. Through this acquisition, Sanofi aims to expand its portfolio in rare inflammatory and cardiovascular-related diseases, strengthen its immunology and inflammation capabilities, and accelerate growth through the addition of a late-stage and commercialized therapy in the recurrent pericarditis space. Kiniksa Pharmaceuticals Limited is a US-based healthcare technology company specializing in developing and commercializing targeted therapies for rare autoinflammatory and cardiovascular conditions, including monoclonal antibody treatments specifically approved for recurrent pericarditis.

Major companies operating in the recurrent pericarditis market are Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Lonza Group AG, Moderna Inc., and WuXi Biologics (Cayman) Inc.

Tariffs on specialty drugs, biologic agents, and diagnostic equipment are increasing treatment and monitoring costs in the recurrent pericarditis market. Import duties on biologic therapies and advanced imaging systems are impacting high value treatment segments the most. Regions that rely heavily on imported biologics, especially in emerging markets, are facing reimbursement and pricing pressure. Healthcare providers are adjusting procurement strategies and seeking regional suppliers. In some countries, tariffs are encouraging local production of generic anti inflammatory drugs. This is slightly improving affordability for standard therapies. It is also supporting domestic pharmaceutical manufacturers.

The recurrent pericarditis market research report is one of a series of new reports that provides recurrent pericarditis market statistics, including recurrent pericarditis industry global market size, regional shares, competitors with a recurrent pericarditis market share, detailed recurrent pericarditis market segments, market trends and opportunities, and any further data you may need to thrive in the recurrent pericarditis industry. This recurrent pericarditis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Recurrent pericarditis is a medical condition involving repeated inflammation episodes of the pericardium following an initial acute occurrence. It is commonly driven by immune mechanisms and is associated with recurring chest discomfort, increased inflammatory indicators, and potential fluid accumulation around the heart.

The key product types for recurrent pericarditis treatment include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, biologics, and other therapies. NSAIDs are medications used to reduce inflammation, relieve pain, and manage symptoms associated with recurrent pericarditis. Diagnosis and assessment involve electrocardiography (ECG), echocardiography, and physical examination. Treatments are delivered via oral and injectable routes, and therapies are applied in colchicine, corticosteroid, and NSAID use cases. End users include hospitals, ambulatory surgical centers, clinics, home care settings, and emergency medical services (EMS).

The recurrent pericarditis market consists of revenues earned by entities by providing services such as cardiology consultations and clinical evaluations, diagnostic imaging and laboratory testing, monitoring of disease recurrence, patient follow-up and long-term care, and patient education and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The recurrent pericarditis market also includes sales of colchicine, immunosuppressive agents, disease-modifying anti-rheumatic drugs (DMARDs), analgesics, and adjunctive cardiovascular medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.